Search results for: Adrian Towse
Filter search results
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…per QALY gained. Draft guidelines are expected to be published for consultation in the week of 15th June 2020. The new model, presented in a forthcoming OHE paper (Berdud, Ferraro and Towse, 2020),…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
…available here. It is also available on the ICER website here. Related Research Pearson SD, Segel C, Cole A, Henshall C, and Towse A. 2019. Policy perspectives on alternative…
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…and Towse and Silverman 2022 have proposed using G7+EU as the denominator, giving an EU share of the global incentive of 34-39% depending on the date and exchange rates used….
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…to believe that £15,000 per QALY is not a reliable estimate of the opportunity cost of spending. In fact, in an analysis of this estimate, Zamora and Towse (2023) identify several sets…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
…more information on this report please contact Margherita Neri. Neri, M., Towse, A. and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward. OHE Briefing. London:…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
…Cole, A., Towse, A. and Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper . OHE Briefing, London: Office of Health Economics. Related research Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and…
Patient Preferences for Diagnostic Tests Aimed at Managing Antimicrobial Resistance
7 October 2019
…European Study of Patient Preferences for Novel Diagnostics to Tackle Antimicrobial Resistance. Applied Health Economics & Health Policy. DOI. Neri, M., Hampson, G., Henshall, C. and Towse, A., 2019. HTA…
A Final MVAC Blueprint—and the Start of an R&D Revolution?
6 February 2020
…available here. (2) Rachel Silverman is a Policy Fellow at the CGD, Kalipso Chalkidou is Director of Global Health Policy and Senior Fellow at the CGD. Citation Chalkidou, K., Garau, M., Silverman, R., and Towse A. (2020)….
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…Towse (2020) propose a supply and demand model to identify the optimal threshold, based on the framework by Pandey et al. (2018), which has been discussed by the PMPRB Working…